文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

无创与有创呼吸管理策略在成人急性低氧性呼吸衰竭中的疗效:系统评价与网络荟萃分析

Efficacy of non-invasive and invasive respiratory management strategies in adult patients with acute hypoxaemic respiratory failure: a systematic review and network meta-analysis.
PubMed 文献 · Crit Care · 2021-11-29
一句话结论在成人急性低氧性呼吸衰竭中,以标准氧疗为参照,CPAP与死亡率显著降低相关(RR 0.55),而PSV和HFNO未达显著。

本研究为系统评价与网络荟萃分析,纳入25项随机对照试验(3,302例成人急性低氧性呼吸衰竭患者,27项比较),比较CPAP、压力支持通气(PSV)、经鼻高流量氧疗(HFNO)、标准氧疗(SOT)与有创机械通气(IMV)的疗效。以SOT为参照,CPAP与死亡率显著降低相关(RR 0.55;95%CI 0.31-0.95;极低确定性),PSV(RR 0.81;95%CI 0.62-1.06;低确定性)和HFNO(RR 0.90;95%CI 0.65-1.25;极低确定性)与死亡率降低无显著相关。与IMV相比,无任何无创呼吸管理策略与死亡率显著降低相关,所有证据确定性均为极低。作者认为,在de novo AHRF患者中行无创通气时,应避免过高潮气量和肺损伤;尽管部分患者需要压力支持,但应谨慎应用。

要点

  • 以SOT为参照,CPAP与死亡率显著降低相关(RR 0.55;95%CI 0.31-0.95;极低确定性)。
  • 以SOT为参照,PSV(RR 0.81;95%CI 0.62-1.06;低确定性)与HFNO(RR 0.90;95%CI 0.65-1.25;极低确定性)与死亡率降低无显著相关。
  • 与IMV相比,无任何无创呼吸管理策略与死亡率显著降低相关,所有证据确定性均为极低。
  • 降低短期死亡率概率排名:CPAP最高(SUCRA 93.2),其次PSV(65.0)、HFNO(44.1),IMV与SOT并列最差(均为23.9)。
  • 作者认为,在de novo AHRF患者中行无创通气时,应避免过高潮气量和肺损伤;压力支持应谨慎应用。

适用人群与场景

  • 成人急性低氧性呼吸衰竭(AHRF)患者。

处置流程与药物剂量

  • 在de novo AHRF患者中行无创通气时,应避免过高潮气量和肺损伤(作者认为)。
  • 压力支持通气(PSV)应谨慎应用,因可能导致过高潮气量和肺损伤(作者认为)。

研究设计与关键结果

  • 系统评价与网络荟萃分析纳入25项随机对照试验,共3,302例成人AHRF患者,27项比较。
  • 以SOT为参照,CPAP与死亡率显著降低相关(RR 0.55;95%CI 0.31-0.95;极低确定性)。
  • 以SOT为参照,PSV与死亡率降低无显著相关(RR 0.81;95%CI 0.62-1.06;低确定性)。
  • 以SOT为参照,HFNO与死亡率降低无显著相关(RR 0.90;95%CI 0.65-1.25;极低确定性)。
  • 与IMV相比,无任何无创呼吸管理策略与死亡率显著降低相关,所有证据确定性均为极低。
  • 降低短期死亡率概率排名(SUCRA值):CPAP 93.2、PSV 65.0、HFNO 44.1、IMV 23.9、SOT 23.9。

证据类型、等级与局限

  • 证据类型:系统评价与网络荟萃分析(纳入随机对照试验)。
  • 证据确定性:CPAP为极低确定性;PSV为低确定性;HFNO为极低确定性;与IMV比较的所有证据确定性均为极低。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在de novo AHRF患者中行无创通气时,应避免过高潮气量和肺损伤(作者认为)。
  • 尽管部分患者需要压力支持,但应谨慎应用,因可能导致过高潮气量和肺损伤(作者认为)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Although non-invasive respiratory management strategies have been implemented to avoid intubation, patients with de novo acute hypoxaemic respiratory failure (AHRF) are high risk of treatment failure. In the previous meta-analyses, the effect of non-invasive ventilation was not evaluated according to ventilation modes in those patients. Furthermore, no meta-analyses comparing non-invasive respiratory management strategies with invasive mechanical ventilation (IMV) have been reported. We performed a network meta-analysis to compare the efficacy of non-invasive ventilation according to ventilation modes with high-flow nasal oxygen (HFNO), standard oxygen therapy (SOT), and IMV in adult patients with AHRF.

METHODS: The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, and Ichushi databases were searched. Studies including adults with AHRF and randomized controlled trials (RCTs) comparing two different respiratory management strategies (continuous positive airway pressure (CPAP), pressure support ventilation (PSV), HFNO, SOT, or IMV) were reviewed.

RESULTS: We included 25 RCTs (3,302 participants: 27 comparisons). Using SOT as the reference, CPAP (risk ratio [RR] 0.55; 95% confidence interval [CI] 0.31-0.95; very low certainty) was associated significantly with a lower risk of mortality. Compared with SOT, PSV (RR 0.81; 95% CI 0.62-1.06; low certainty) and HFNO (RR 0.90; 95% CI 0.65-1.25; very low certainty) were not associated with a significantly lower risk of mortality. Compared with IMV, no non-invasive respiratory management was associated with a significantly lower risk of mortality, although all certainties of evidence were very low. The probability of being best in reducing short-term mortality among all possible interventions was higher for CPAP, followed by PSV and HFNO; IMV and SOT were tied for the worst (surface under the cumulative ranking curve value: 93.2, 65.0, 44.1, 23.9, and 23.9, respectively).

CONCLUSIONS: When performing non-invasive ventilation among patients with de novo AHRF, it is important to avoid excessive tidal volume and lung injury. Although pressure support is needed for some of these patients, it should be applied with caution because this may lead to excessive tidal volume and lung injury. Trial registration protocols.io (Protocol integer ID 49375, April 23, 2021). https://doi.org/10.17504/protocols.io.buf7ntrn .

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Sakuraya M, Okano H, Masuyama T, et al. Efficacy of non-invasive and invasive respiratory management strategies in adult patients with acute hypoxaemic respiratory failure: a systematic review and network meta-analysis. Crit Care. 2021. PMID: 34844655. doi:10.1186/s13054-021-03835-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。